Success Metrics

Clinical Success Rate

80.0%

Based on 4 completed trials

Completion Rate

80%(4/5)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Terminated

1(20%)

Phase Distribution

Ph phase_2

20%

Ph phase_3

80%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 2Efficacy & side effects

1(20.0%)

Phase 3Large-scale testing

4(80.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(4)

Terminated(1)

Detailed Status

Completed4

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

80.0%

Most Advanced

Phase 3

Trials by Phase

Phase 21 (20.0%)

Phase 34 (80.0%)

Trials by Status

terminated120%

completed480%

Recent Activity

0 active trials

Showing 5 of 5

terminatedphase_3

Study of Biostate for Treatment of Children With Hemophilia A Complicated by Antibody Development

NCT01445197

completedphase_2

Study of a pd VWF/FVIII Concentrate, Biostate®, in Subjects With Von Willebrand Disease

NCT00941616

completedphase_3

Clinical Trials (5)

Showing 5 of 5 trials

NCT01445197Phase 3

Study of Biostate for Treatment of Children With Hemophilia A Complicated by Antibody Development

Terminated

NCT00941616Phase 2

Study of a pd VWF/FVIII Concentrate, Biostate®, in Subjects With Von Willebrand Disease

Completed

NCT01213446Phase 3

Study of Biostate® in Children With Von Willebrand Disease

Completed

NCT01224808Phase 3

Extension Study of Biostate in Subjects With Von Willebrand Disease

Completed

NCT01229007Phase 3

Study of Biostate® in Children With Hemophilia A

Completed

All 5 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 5